<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506814</url>
  </required_header>
  <id_info>
    <org_study_id>UR Re-ablation Paroxysmal AF</org_study_id>
    <nct_id>NCT04506814</nct_id>
  </id_info>
  <brief_title>Endocardial Vs Epicardial Ablation for Recurrent Paroxysmal AF</brief_title>
  <acronym>REPEAL-AF</acronym>
  <official_title>Comparison of Repeat Endocardial PVI Vs Epicardial Posterior Wall Isolation and LAA Clip Plus PVI for Recurrent Atrial Fibrillation After Prior PVI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no current accepted and predictably effective ablative therapy for patients with&#xD;
      recurrent paroxysmal atrial fibrillation after prior pulmonary vein isolation (PVI). This&#xD;
      study will compare redo PVI with hybrid epicardial ablation incorporating posterior wall&#xD;
      isolation and LAA clip, and redo PVI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In these redo ablation patients, the ideal re-ablation strategy is unknown and many&#xD;
      techniques have been proposed but there is no consensus nor strong clinical trial data.&#xD;
&#xD;
      This treatment gap prompted the development of a combined minimally invasive epicardial and&#xD;
      endocardial ablation (&quot;Convergent&quot;) procedure. During the last decade, this &quot;hybrid&quot; approach&#xD;
      has garnered increasing acceptance in clinical practice, with several reports of promising&#xD;
      antiarrhythmic outcomes in challenging disease states, as well as modifications to maximize&#xD;
      safety and clinical outcomes. One key aspect of this approach is that it targets key drivers&#xD;
      of AF including the PVs but also the left atrial posterior wall (LAPW), combining endocardial&#xD;
      and epicardial energy delivery. The LAPW (or &quot;PV myocardium&quot;) shares similar embryological&#xD;
      origins and electrophysiological properties with the PVs, is predisposed to develop fibrosis,&#xD;
      and thus recognized as an important source of AF. Recently, the CONVERGE randomized clinical&#xD;
      trial demonstrated superiority of this hybrid approach compared to PVI in patients with&#xD;
      persistent AF.&#xD;
&#xD;
      The left atrial appendage (LAA) has also been designated as a potential important trigger&#xD;
      site of AF, and if isolated, may result in improved post-ablation AF outcomes. Although&#xD;
      catheter-based isolation is controversial due to the potential to increase the risk of&#xD;
      stroke, surgical exclusion of the LAA by placement of an occlusive clip has been suggested to&#xD;
      be both antiarrhythmic and anti-thrombotic. Thus it is proposed in this trial to incorporate&#xD;
      the LAA clip within the hybrid procedure.&#xD;
&#xD;
      Given the sheer volume of patients undergoing ablation of AF and the predictable necessity to&#xD;
      perform repeat ablation procedures on a portion of these patients, the need for a proven redo&#xD;
      ablation strategy is self-evident. The investigators thus propose a randomized clinical trial&#xD;
      to determine if there is incremental efficacy by performing LAPW/LAA isolation via a hybrid&#xD;
      approach in comparison to the conventional redo PVI alone in patients with paroxysmal AF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation &gt; 30 secs</measure>
    <time_frame>At 1 year</time_frame>
    <description>Based on serial 7-day Holter recordings</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Recurrent Paroxysmal Atrial Fibrillation Despite Prior Pulmonary Vein Isolation</condition>
  <arm_group>
    <arm_group_label>Endocardial PVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocardial complete PVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimally invasive surgical hybrid ablation using the convergent approach plus LAA exclusion using the clip</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endocardial PVI</intervention_name>
    <description>Catheter based PVI</description>
    <arm_group_label>Endocardial PVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI</intervention_name>
    <description>Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI</description>
    <arm_group_label>Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age &gt; 18 years&#xD;
&#xD;
          2. Symptomatic paroxysmal AF despite prior 1 or 2 PVI procedures within past 10 years&#xD;
             (paroxysmal AF lasting up to 7 days before spontaneous termination)&#xD;
&#xD;
          3. Eligible for referral for re-ablation based on current guidelines&#xD;
&#xD;
          4. LA diameter &lt; 6.0 cms on transthoracic echo&#xD;
&#xD;
          5. Willingness to comply with post-procedural follow-up requirements and to sign informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus,&#xD;
             contraindication to anticoagulation)&#xD;
&#xD;
          2. Prior history of open heart surgery&#xD;
&#xD;
          3. Prior history of pericarditis or pericardiocentesis&#xD;
&#xD;
          4. Prior history of stroke/TIA/systemic embolism&#xD;
&#xD;
          5. NYHA class IV congestive heart failure or LVEF &lt; 25%&#xD;
&#xD;
          6. Persistent or longstanding persistent AF (duration &gt; 1 year)&#xD;
&#xD;
          7. Coronary revascularization or valve surgery within 3 months&#xD;
&#xD;
          8. Prior valve surgery using a mechanical prosthesis&#xD;
&#xD;
          9. An estimated glomerular filtration rate (eGFR) &lt; 45mL/min/1.73m2, using the MDRD&#xD;
             calculation&#xD;
&#xD;
         10. Life expectancy &lt;1 year for any medical condition&#xD;
&#xD;
         11. AF due to reversible cause e.g. hyperthyroid state&#xD;
&#xD;
         12. Women who are pregnant or plan to become pregnant during the course of the trial**&#xD;
             Note: Women of childbearing potential must have a negative pregnancy test within 7&#xD;
             days prior to randomization.&#xD;
&#xD;
         13. Participation in other clinical trials that will affect the objectives of this study&#xD;
&#xD;
         14. History of non-compliance to medical therapy&#xD;
&#xD;
         15. Inability or unwillingness to provide informed consent&#xD;
&#xD;
         16. Resides at such a distance from the enrolling site so travel to follow-up visits would&#xD;
             be unusually difficult&#xD;
&#xD;
         17. Does not anticipate residing in the vicinity of the enrolling site for the duration of&#xD;
             the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Steinberg, MD</last_name>
    <phone>9734364155</phone>
    <email>jsteinberg@smgnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Short Hills</city>
        <state>New Jersey</state>
        <zip>07078</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan Steinberg</last_name>
      <phone>973-436-4155</phone>
      <email>jsteinberg@smgnj.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jonathan Steinberg</investigator_full_name>
    <investigator_title>Collaborator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

